Regulacje i polityka gospodarcza · 22/10/2021
Ankarys Therapeutics to Receive Exclusive Patent License for CD28H Chimeric Antigen Receptors
The National Institute of Allergy and Infectious Diseases is considering granting Ankarys Therapeutics an exclusive patent license to use CD28H domain-containing chimeric antigen receptors and related methods, as outlined in patent applications listed in the notice.